4995 Murphy Canyon Road
Suite 300
San Diego, CA 92123
United States
760 471 8536
https://www.conduitpharma.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 7
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. David Joszef Tapolczay | CEO & Director | 419,8k | N/D | 1959 |
Mr. James Bligh | Interim CFO & Director | 533,35k | N/D | 1989 |
Dr. Joanne M. Holland | Chief Scientific Officer | N/D | N/D | 1975 |
Mr. Bill Begien | Senior VP of Investor Relations | N/D | N/D | N/D |
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
L'ISS Governance QualityScore di Conduit Pharmaceuticals Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.